Search Results - "Chien, Caly"

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model by Van den Bergh, An, Snoeys, Jan, De Zwart, Loeckie, Ward, Peter, Lopez-Gitlitz, Angela, Ouellet, Daniele, Monshouwer, Mario, Chien, Caly

“…Background Apalutamide is predominantly metabolized via cytochrome P450 (CYP) 2C8 and CYP3A4, whose contributions change due to autoinduction with repeated…”
Get full text

Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study by T’jollyn, Huybrecht, Ackaert, Oliver, Chien, Caly, Lopez-Gitlitz, Angela, McCarthy, Sharon, Ruixo, Carlos Perez, Karsh, Lawrence, Chi, Kim, Chowdhury, Simon, Ruixo, Juan-Jose Perez, Agarwal, Neeraj

“…Purpose Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer…”
Get full text

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects by Pérez-Ruixo, Carlos, Pérez-Blanco, Jonás Samuel, Chien, Caly, Yu, Margaret, Ouellet, Daniele, Pérez-Ruixo, Juan-José, Ackaert, Oliver

“…Background Apalutamide is a next-generation androgen receptor inhibitor approved for treatment of subjects with high-risk, non-metastatic, castration-resistant…”
Get full text

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer by Duran, Ignacio, Carles, Joan, Bulat, Iurie, Hellemans, Peter, Mitselos, Anna, Ward, Peter, Jiao, James, Armas, Danielle, Chien, Caly

“…Background and Objectives Two phase I studies assessed the drug–drug interaction potential of apalutamide as a substrate and perpetrator. Methods Study A…”
Get full text

Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes by de Vries, Ronald, Jacobs, Frank, Mannens, Geert, Snoeys, Jan, Cuyckens, Filip, Chien, Caly, Ward, Peter

“…In this phase 1 study, the absolute bioavailability and absorption, metabolism, and excretion (AME) of apalutamide, a competitive inhibitor of the androgen…”
Get full text

Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States by Wang-Gillam, Andrea, Schelman, William, Ukrainskyj, Stacey, Chien, Caly, Gonzalez, Martha, Yang, Zhao, Kania, Marek, Yeckes-Rodin, Heather

“…Summary This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquintinib in United States (U.S.)…”
Get full text

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer by Dasari, Arvind, Sobrero, Alberto, Yao, James, Yoshino, Takayuki, Schelman, William, Yang, Zhao, Chien, Caly, Kania, Marek, Tabernero, Josep, Eng, Cathy

“…Fruquintinib, a novel, highly selective, small-molecule tyrosine kinase inhibitor of VEGF receptors (VEGFRs)-1, -2 and -3, is approved in China for the…”
Get full text

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma by von Tresckow, Bastian, Morschhauser, Franck, Ribrag, Vincent, Topp, Max S, Chien, Caly, Seetharam, Shobha, Aquino, Regina, Kotoulek, Sonja, de Boer, Carla J, Engert, Andreas

“…This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for…”
Get full text

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect by Meanwell, Nicholas A, Gao, Min, Nettles, Richard E, Belema, Makonen, Snyder, Lawrence B, Nguyen, Van N, Fridell, Robert A, Serrano-Wu, Michael H, Langley, David R, Sun, Jin-Hua, O’Boyle II, Donald R, Lemm, Julie A, Wang, Chunfu, Knipe, Jay O, Chien, Caly, Colonno, Richard J, Grasela, Dennis M, Hamann, Lawrence G

“…The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a…”
Get full text

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma by Strati, Paolo, Chraniuk, Dominik, González-Barca, Eva, Taszner, Michal, Pillai, Rathi, Chien, Caly, Nanda, Shivani, Rudinski, Mark, Jayaprakash, Vijayvel, Hahka-Kemppinen, Marjo, Kania, Marek

“…Background: Spleen tyrosine kinase (Syk) plays an integral role in B-cell receptor signaling critical in the development and survival of several subtypes of…”
Get full text

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer by Alyamani, Mohammad, Emamekhoo, Hamid, Park, Sunho, Taylor, Jennifer, Almassi, Nima, Upadhyay, Sunil, Tyler, Allison, Berk, Michael P, Hu, Bo, Hwang, Tae Hyun, Figg, William Douglas, Peer, Cody J, Chien, Caly, Koshkin, Vadim S, Mendiratta, Prateek, Grivas, Petros, Rini, Brian, Garcia, Jorge, Auchus, Richard J, Sharifi, Nima

“…A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) missense that increases metabolic flux from…”
Get full text

FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC) by Dasari, Arvind, Yao, James C., Sobrero, Alberto F., Yoshino, Takayuki, Schelman, William R., Nanda, Shivani, Chien, Caly, Pu, Su-Fen, Kania, Marek K., Tabernero, Josep, Eng, Cathy

“…Abstract only TPS154 Background: Pts with mCRC have limited treatment options following progression on standard therapies. Current standard of care (SOC) after…”
Get full text

Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer by Perez-Ruixo, Carlos, Ackaert, Oliver, Ouellet, Daniele, Chien, Caly, Uemura, Hiroji, Olmos, David, Mainwaring, Paul, Lee, Ji Youl, Yu, Margaret K, Perez-Ruixo, Juan Jose, Smith, Matthew R, Small, Eric J

“…To evaluate the relationship between exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, and selected clinical efficacy and safety…”
Get full text

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer by Chi, Kim N., Spratlin, Jennifer, Kollmannsberger, Christian, North, Scott, Pankras, Catherine, Gonzalez, Martha, Bernard, Apexa, Stieltjes, Hans, Peng, Lixian, Jiao, James, Acharya, Milin, Kheoh, Thian, Griffin, Thomas W., Yu, Margaret K., Chien, Caly, Tran, Nam Phuong

“…Food effect on abiraterone pharmacokinetics and safety on abiraterone acetate coadministration with low‐fat or high‐fat meals was examined in healthy subjects…”
Get full text

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study by Posadas, Edwin M, Chi, Kim N, de Wit, Ronald, de Jonge, Maja J A, Attard, Gerhardt, Friedlander, Terence W, Yu, Margaret K, Hellemans, Peter, Chien, Caly, Abrams, Charlene, Jiao, Juhui J, Saad, Fred

“…Apalutamide is a next-generation androgen receptor (AR) inhibitor approved for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and…”
Get full text

Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug by Brown, Jonathan, Chien, Caly, Timmins, Peter, Dennis, Andrew, Doll, Walter, Sandefer, Erik, Page, Richard, Nettles, Richard E, Zhu, Li, Grasela, Dennis

“…BMS-663068 is a phosphonooxymethyl ester prodrug under development for the treatment of HIV/AIDS. The prodrug is designed to overcome the solubility-limited…”
Get more information

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy by Genovese, Mark C, Hsia, Elizabeth, Belkowski, Stanley M, Chien, Caly, Masterson, Tara, Thurmond, Robin L, Manthey, Carl L, Yan, Xiaoyu David, Ge, Tingting, Franks, Carol, Greenspan, Andrew

“…To assess the efficacy and safety of JNJ-40346527, a selective inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase that acts to inhibit macrophage…”
Get full text

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors by Dasari, Arvind, Hamilton, Erika P., Falchook, Gerald S., Wang, Judy S., Li, Daneng, Sung, Max W., Chien, Caly, Nanda, Shivani, Tucci, Christopher, Hahka-Kemppinen, Marjo, Paulson, Andrew Scott

“…Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1–3; fibroblast growth factor receptor-1; colony-stimulating factor 1…”
Get full text

Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection by Scola, Paul M., Wang, Alan Xiangdong, Good, Andrew C., Sun, Li-Qiang, Combrink, Keith D., Campbell, Jeffrey A., Chen, Jie, Tu, Yong, Sin, Ny, Venables, Brian L., Sit, Sing-Yuen, Chen, Yan, Cocuzza, Anthony, Bilder, Donna M., D’Andrea, Stanley, Zheng, Barbara, Hewawasam, Piyasena, Ding, Min, Thuring, Jan, Li, Jianqing, Hernandez, Dennis, Yu, Fei, Falk, Paul, Zhai, Guangzhi, Sheaffer, Amy K., Chen, Chaoqun, Lee, Min S., Barry, Diana, Knipe, Jay O., Li, Wenying, Han, Yong-Hae, Jenkins, Susan, Gesenberg, Christoph, Gao, Qi, Sinz, Michael W., Santone, Kenneth S., Zvyaga, Tatyana, Rajamani, Ramkumar, Klei, Herbert E., Colonno, Richard J., Grasela, Dennis M., Hughes, Eric, Chien, Caly, Adams, Stephen, Levesque, Paul C., Li, Danshi, Zhu, Jialong, Meanwell, Nicholas A., McPhee, Fiona

“…The discovery of BMS-605339 (35), a tripeptidic inhibitor of the NS3/4A enzyme, is described. This compound incorporates a cyclopropyl­acylsulfonamide moiety…”
Get full text

Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing by Inoue, Kouichi, Shishido, Akira, Vaccaro, Nicole, Jiao, James, Stieltjes, Hans, Bernard, Apexa, Yu, Margaret, Chien, Caly

“…Purpose Abiraterone acetate (AA) was recently approved for castration-resistant prostate cancer in Japan. Two phase 1 studies were conducted to assess the…”
Get full text